Chemical Metabolic Inhibitors For The Treatment Of Blood-Borne Cancers.

Abstract : : Tumor cells, including leukemic cells, remodel their bioenergetic system in favor of aerobic glycolysis. This process is called "the Warburg effect" and offers an attractive pharmacological target to preferentially eliminate malignant cells. In addition, recent results show that metabolic changes can be linked to tumor immune evasion. Mouse models demonstrate the importance of this metabolic remodeling in leukemogenesis. Some leukemias, although treatable, remain incurable and resistance to chemotherapy produces an elevated percentage of relapse in most leukemia cases. Several groups have targeted the specific metabolism of leukemia cells in preclinical and clinical studies to improve the prognosis of these patients, i.e. using L-asparaginase to treat pediatric acute lymphocytic leukemia (ALL). Additional metabolic drugs that are currently being used to treat other diseases or tumors could also be exploited for leukemia, based on preclinical studies. Finally, we discuss the potential use of several metabolic drugs in combination therapies, including immunomodulatory drugs (IMiDs) or immune cell-based therapies, to increase their efficacy and reduce side effects in the treatment of hematological cancers.
Type de document :
Article dans une revue
Current Medicinal Chemistry Anticancer Agents, Bentham Science Publishers, 2014, 14 (2), pp.223-32
Liste complète des métadonnées

Littérature citée [109 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00916461
Contributeur : Monique Frei <>
Soumis le : mardi 10 décembre 2013 - 12:10:20
Dernière modification le : lundi 11 juin 2018 - 16:46:01
Document(s) archivé(s) le : samedi 8 avril 2017 - 05:36:59

Fichier

chemical_metabolic_inhibitorBe...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Martin Villalba, Nuria Lopez-Royuela, Ewelina Krzywinska, Moeez Rathore, Robert Hipskind, et al.. Chemical Metabolic Inhibitors For The Treatment Of Blood-Borne Cancers.. Current Medicinal Chemistry Anticancer Agents, Bentham Science Publishers, 2014, 14 (2), pp.223-32. 〈inserm-00916461〉

Partager

Métriques

Consultations de la notice

943

Téléchargements de fichiers

89